Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14469112 | 0.87 | RAB9A (0.33) | ERN1ALDH1A1CYP1A2CYP2C9HPGD | |
| SCHEMBL12728128 | 0.75 | BRD4 (0.31) | — | |
| SCHEMBL14468974 | 0.66 | PNMT (0.36) | — | |
| SCHEMBL28092444 | 0.65 | CYP1A2 (0.43) | ERN1ALDH1A1CYP1A2 | |
| SCHEMBL27856092 | 0.63 | MYC (0.34) | ERN1HPGD | |
| SCHEMBL27704528 | 0.61 | TGM2 (0.40) | ERN1RAB9A | |
| SCHEMBL28026721 | 0.61 | CA1 (0.36) | ERN1ALDH1A1CYP1A2 | |
| SCHEMBL28917151 | 0.61 | CA1 (0.33) | ERN1ALDH1A1CYP1A2 | |
| SCHEMBL18748412 | 0.61 | S100A4 (0.41) | ERN1ALDH1A1CYP1A2 | |
| SCHEMBL25726443 | 0.61 | MAPK1 (0.40) | ALDH1A1CYP1A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | ABAT, BPTF, TNNT2 | ERN1 2731/4885ALDH1A1 224/4885CYP1A2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.